Skip to main content
. 2021 Mar 8;11(3):e044149. doi: 10.1136/bmjopen-2020-044149

Table 1.

Parameters estimation from other literature where the means and corresponding credible intervals are shown in the parenthesis

Parameter Definition Value Calculation Reference
R0 Basic reproduction number 3.1 (1.9–6.5) 41
θ Symptomatic rate 0.792 (0.568–0.815) 42–44
β2 Infection rate for symptomatic transmissions 0.62 (0.38–1.3) R0InfectiousPeriodSevere 45
α Reduction of infection rate for asymptomatic transmission 0.55 (0.46–0.62) 46
β1 Infection rate for asymptomatic transmissions 0.341 (0.175–0.806)
γ1 Clearance rate for asymptomatic/mild cases 0.170 (0.0526–0.287) 1InfectiousPeriodMild 42 46
γ2 Clearance rate for symptomatic non-severe cases 0.238 (0.143–0.333) 1InfectiousPeriodsympt 47–49
γ3 Clearance rate for symptomatic severe cases 0.238 (0.143–0.333) 1InfectiousPeriodsympt 47–49
μ Incubation rate 0.202 (0.101–0.364) 1IncubationTime 50 51
δ Severe case fatality rate 0.244 (0.209–0.280) 17 52
κ Increase in rate of progression to severe disease in populations with TB or HIV/AIDS 2.14 (1.1–2.7) 16 17
Ages 0–64 Ages 65–79 Ages ≥80
h Rate of progression to severe disease* 0.202 (0.167–0.237) 0.361 (0.286–0.435) 0.471 (0.308–0.634) 53 54
κh Rate of progression to severe disease in populations with TB and/or HIV/AIDS 0.432 (0.222–0.545)

*Age groups are: 0–59, 60–69, 70+; 0–64, 65–74, 65+, US hospitalisation rate used as a proxy for severe disease progression.

TB, tuberculosis.